Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Icecure Medical ( (ICCM) ) just unveiled an announcement.
On February 23, 2026, IceCure Medical announced it has completed five-year patient follow up in its ICESECRET clinical trial evaluating the ProSense® cryoablation system for small renal masses in kidney cancer patients. The prospective, multicenter single-arm study in Israel enrolled 114 patients with 138 lesions of up to 5 cm, with safety monitored through procedure-related adverse events and local recurrence assessed via CT over scheduled visits from six weeks to five years.
Previously reported three-year interim data from 111 patients showed ProSense® achieved an 88.7% recurrence‑free rate and supported its profile as a safe and effective option for patients who are ineligible for kidney-preserving surgery. With kidney cancer incidence rising globally and ProSense® already approved for kidney tumors in major markets, the completion of long-term follow up positions IceCure to finalize analysis in the second quarter of 2026 and potentially strengthen clinical adoption of minimally invasive, nephron-sparing cryoablation for this growing patient population.
The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of benign and cancerous tumors. Its flagship minimally invasive ProSense® system targets breast, kidney, bone and lung cancers and is marketed in the U.S., Europe, Asia and other regions for approved indications, including low-risk breast cancer in older women and benign and malignant kidney tumors.
Average Trading Volume: 297,815
Technical Sentiment Signal: Sell
Current Market Cap: $39.86M
Learn more about ICCM stock on TipRanks’ Stock Analysis page.